Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New antiviral agents for the treatment of hepatitis C: ABT-450.

Expert opinion on pharmacotherapy - 1 Apr 2014

Carrion Andres F, Gutierrez Julio, Martin Paul

Abstract excerpt

INTRODUCTION: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclopropanes
Share to Lactams, Macrocyclic
Share to Macrocyclic Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proline

Share to Ribavirin

Share to Ritonavir

Share to Sulfonamides

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24517400
DOI: 10.1517/14656566.2014.889116
PMCID: PMC6658177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New antiviral agents for the treatment of hepatitis C: ABT-450.PMID 24517400Read ↗

ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.Semantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450Semantic proximity Read ↗

Exploratory study of oral combination antiviral therapy for hepatitis C.Semantic proximity Read ↗

Sofosbuvir and ABT-450: terminator of hepatitis C virus?Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.Semantic proximity Read ↗

A review of current anti-HCV treatment regimens and possible future strategies.Semantic proximity Read ↗

Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Semantic proximity Read ↗

Drugs in development for chronic hepatitis C: a promising future.Semantic proximity Read ↗

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.